We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
-3.65%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$342M
AUM Growth
-$111M
Cap. Flow
-$71.8M
Cap. Flow %
-21.01%
Top 10 Hldgs %
35.85%
Holding
99
New
15
Increased
34
Reduced
31
Closed
19

Top Buys

Rank Stock Value
1
THC icon
Tenet Healthcare
THC
+$8.15M
2
IRTC icon
iRhythm Holdings
IRTC
+$5.39M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$5.36M
4
LEGN icon
Legend Biotech
LEGN
+$4.76M
5
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$4.36M

Top Sells

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$13M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$10.9M
3
AVTR icon
Avantor
AVTR
+$8.89M
4
DXCM icon
DexCom
DXCM
+$8.82M
5
DHR icon
Danaher
DHR
+$6.18M

Sector Composition

Rank Sector Weight
1 Healthcare 96.94%
2 Industrials 2.69%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IDXX icon
26
Idexx Laboratories
IDXX
$45B
$5.14M 1.5%
9,388
-1,582
-14% -$832K
APEN
27
DELISTED
Apollo Endosurgery, Inc.
APEN
$4.9M 1.43%
810,411
-108,074
-12% -$659K
SRRA
28
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$4.87M 1.43%
+151,915
New +$4.36M
TFX icon
29
Teleflex
TFX
$6.03B
$4.43M 1.3%
+12,500
New +$4.12M
LEGN icon
30
Legend Biotech
LEGN
$3.99B
$4.38M 1.28%
+120,473
New +$4.76M
SDGR icon
31
Schrodinger
SDGR
$1.39B
$3.95M 1.16%
115,891
+48,099
+71% +$1.46M
KROS icon
32
Keros Therapeutics
KROS
$222M
$3.95M 1.16%
72,690
+2,829
+4% +$145K
HBIO icon
33
Harvard Bioscience
HBIO
$27.8M
$3.94M 1.15%
63,383
+9,675
+18% +$572K
FULC icon
34
Fulcrum Therapeutics
FULC
$284M
$3.89M 1.14%
164,453
-85,653
-34% -$1.21M
OM icon
35
Outset Medical
OM
$84.6M
$3.71M 1.08%
5,440
+2,286
+72% +$1.38M
SUPN icon
36
Supernus Pharmaceuticals
SUPN
$2.78B
$3.52M 1.03%
108,954
+4,240
+4% +$130K
PODD icon
37
Insulet
PODD
$10.1B
$3.38M 0.99%
12,671
-4,329
-25% -$1.06M
MASS icon
38
908 Devices
MASS
$414M
$3.33M 0.97%
+175,000
New +$3.01M
ANIP icon
39
ANI Pharmaceuticals
ANIP
$1.73B
$3.03M 0.89%
107,911
-29,315
-21% -$1.09M
PHLT
40
DELISTED
Performant Healthcare Inc
PHLT
$2.98M 0.87%
957,083
+107,083
+13% +$252K
CRL icon
41
Charles River Laboratories
CRL
$13.6B
$2.84M 0.83%
10,000
-15,901
-61% -$4.9M
MRVI icon
42
Maravai LifeSciences
MRVI
$861M
$2.73M 0.8%
77,389
-21,299
-22% -$714K
IMGO
43
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
$2.69M 0.79%
139,751
+29,751
+27% +$617K
BCYC
44
Bicycle Therapeutics
BCYC
$284M
$2.51M 0.74%
57,295
-7,505
-12% -$350K
MNKD icon
45
MannKind Corp
MNKD
$1.24B
$2.48M 0.73%
675,403
+409,548
+154% +$1.5M
HCAT icon
46
Health Catalyst
HCAT
$135M
$2.08M 0.61%
79,746
+27,068
+51% +$768K
MDGL icon
47
Madrigal Pharmaceuticals
MDGL
$12.4B
$1.99M 0.58%
20,230
-8,440
-29% -$712K
KRMD icon
48
KORU Medical Systems
KRMD
$152M
$1.92M 0.56%
672,457
+74,847
+13% +$224K
ALT icon
49
Altimmune
ALT
$570M
$1.89M 0.55%
309,586
+46,112
+18% +$340K
GOSS icon
50
Gossamer Bio
GOSS
$86.8M
$1.74M 0.51%
200,185
-346,236
-63% -$3.34M
1
2
3 4

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q1 2022 Portfolio in Review

As of Q1 2022, Parkman Healthcare Partners held 99 positions worth $342M, down 25% from $453M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Parkman Healthcare Partners withdrew a net $71.8M in Q1 2022, closing 19 positions and reducing 31 holdings. Its most notable exit was HCA Healthcare, an estimated $13M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

Against the trend, Parkman Healthcare Partners opened a new position in Neurocrine Biosciences worth $5.93M.

  • Parkman Healthcare Partners's largest Q1 2022 buy was Neurocrine Biosciences: 63,234 shares worth $5.93M.
  • Parkman Healthcare Partners added most to Tenet Healthcare in Q1 2022, an estimated $8.15M increase.
  • Parkman Healthcare Partners's biggest Q1 2022 reduction was Avantor, cutting an estimated $8.89M.
  • Parkman Healthcare Partners fully exited HCA Healthcare in Q1 2022, selling an estimated $13M.
  • Parkman Healthcare Partners's ten largest holdings make up 36% of its $342M portfolio in Q1 2022.
  • Parkman Healthcare Partners opened 15 new positions and closed 19 in Q1 2022.
  • Parkman Healthcare Partners's portfolio value fell 25% quarter-over-quarter to $342M.

Based on Parkman Healthcare Partners's 13F filing for Q1 2022, filed 13 May 2022.